Praxis Precision Medicines will present late-stage epilepsy and movement disorder data at the AAN 2025 Annual Meeting in San Diego.
Quiver AI Summary
Praxis Precision Medicines, Inc. announced its participation in the American Academy of Neurology (AAN) 2025 Annual Meeting, where it will present data from four late-stage programs focused on epilepsy and movement disorders. The event will take place from April 5 to 9, 2025, in San Diego, California, and Praxis aims to showcase its innovative pipeline, including updates from the vormatrigine ENERGY program and new clinical trials enrolling participants in the U.S., Europe, and Latin America. The company will host an In-Booth Speaker Showcase featuring experts in CNS disorders and will present multiple posters on topics related to essential tremor and epilepsy. Praxis is advancing various clinical programs, including relutrigine, vormatrigine, elsunersen, and ulixacaltamide, which target different neurological conditions through their proprietary platforms.
Potential Positives
- Praxis is set to present data from four late-stage programs at a prominent medical conference, highlighting its commitment to advancing treatments for CNS disorders.
- The company is actively engaging with the medical community through a series of presentations and an In-Booth Speaker Showcase, which may enhance collaboration and awareness of its innovative pipeline.
- Praxis has multiple clinical-stage assets that have received FDA and EMA Orphan Drug Designation, which may facilitate expedited development and approval processes for its therapies.
- The announcement underscores Praxis's potential to impact patient care positively by addressing significant unmet medical needs in epilepsy and movement disorders.
Potential Negatives
- Announcement of clinical updates may lead to heightened scrutiny from investors and stakeholders regarding the results of these trials and the company's overall progress in developing its therapies.
- The press release includes multiple references to ongoing studies and pipelines, which implies a lack of finalized data or approvals that could raise concerns about the company’s timelines and execution capabilities.
- The focus on upcoming presentations and networking events could indicate that the company is currently relying heavily on these opportunities to generate interest and momentum, suggesting potential weaknesses in direct clinical advancement or market readiness.
FAQ
What will Praxis present at the AAN 2025 Annual Meeting?
Praxis will present data from its four late-stage programs focused on epilepsy and movement disorders.
Where is Praxis's booth located at the AAN meeting?
Praxis will exhibit at booth #2113 during the AAN 2025 Annual Meeting in San Diego.
What is the focus of Praxis's In-Booth Speaker Showcase?
The In-Booth Speaker Showcase will feature discussions on revolutionary therapies for CNS disorders and key clinical updates.
What are the timelines for Praxis's poster presentations?
Poster presentations are scheduled from April 5 to April 9, 2025, at the AAN event.
What designations has Relutrigine received from the FDA?
Relutrigine has received Orphan Drug Designation and Rare Pediatric Disease Designation for specific types of epilepsy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRAX Insider Trading Activity
$PRAX insiders have traded $PRAX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PRAX stock by insiders over the last 6 months:
- ALEX NEMIROFF (General Counsel and Secretary) sold 8,239 shares for an estimated $660,827
- LAUREN MASTROCOLA (Principal Accounting Officer) sold 5,188 shares for an estimated $424,318
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRAX Hedge Fund Activity
We have seen 86 institutional investors add shares of $PRAX stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 1,083,026 shares (+1345.4%) to their portfolio in Q4 2024, for an estimated $83,349,680
- CORMORANT ASSET MANAGEMENT, LP added 823,219 shares (+94.6%) to their portfolio in Q4 2024, for an estimated $63,354,934
- ASSENAGON ASSET MANAGEMENT S.A. added 548,986 shares (+5437.7%) to their portfolio in Q4 2024, for an estimated $42,249,962
- POINT72 ASSET MANAGEMENT, L.P. removed 511,971 shares (-49.5%) from their portfolio in Q4 2024, for an estimated $39,401,288
- VESTAL POINT CAPITAL, LP removed 440,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $25,317,600
- JANUS HENDERSON GROUP PLC added 405,957 shares (+77.5%) to their portfolio in Q4 2024, for an estimated $31,242,450
- DEEP TRACK CAPITAL, LP removed 389,546 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $22,414,476
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PRAX Analyst Ratings
Wall Street analysts have issued reports on $PRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 10/14/2024
To track analyst ratings and price targets for $PRAX, check out Quiver Quantitative's $PRAX forecast page.
Full Release
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) --
Praxis Precision Medicines
, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present data from its four late-stage programs in epilepsy and movement disorders at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place from April 5 to 9, 2025 in San Diego, California.
“Praxis’s innovative pipeline continues to rapidly advance, with four late-stage programs poised to transform patient care,” said Steven Petrou, Chief Scientific Officer and Co-Founder of Praxis. “At this year’s AAN, we’re excited to present the latest developments across our diverse portfolio, including key clinical updates from the vormatrigine ENERGY program and newly initiated clinical trials actively enrolling patients across the U.S., Europe, and Latin America. We are especially pleased to host an engaging In-Booth Speaker Showcase featuring renowned experts and collaborators who share our mission of revolutionizing therapies for CNS disorders.”
Praxis will have multiple opportunities for visitors to learn more about its portfolio:
Exhibiting
at
booth #2113
where visitors can interact with members of the Praxis team including a dedicated networking event, detailed below
Hosting
an In-Booth Speaker Showcase covering three of its clinical-stage assets, and featuring an exciting line up of leading epilepsy and movement disorders experts, detailed below
Presenting
four unique posters covering two of its clinical-stage assets, detailed below
Praxis Booth
Connect with members of our team at booth #2113 during exhibit hours or join us for the following:
In-Booth Networking Crawl
–
refreshments served
Monday, April 7 | 4:00 PM – 6:00 PM PT | Booth 2113 | Exhibit Hall A-D
In Booth Speaker Showcase
–
Praxis Precision Medicines: Revolutionizing CNS Therapies
Sunday 6 April – Wednesday 9 April | 1:30 PM – 3:30 PM PT | Exhibit Hall A-D
Praxis Poster Presentations
P5-011
:
Spotlight on Essential Tremor Management and Impact: Results from an Online Survey Capturing HCP and Patient Perspectives of Disease Burden
Saturday, April 5 | 11:45 AM – 12:45 PM PT | Exhibit Hall A
P5-012
:
Characteristics of Adult Essential Tremor Patients Seeking Participation in a Decentralized US Clinical Trial: Pre-screener Findings from the Essential3 Program Evaluating Efficacy and Safety of Ulixacaltamide
Saturday, April 5 | 11:45 AM – 12:45 PM PT | Exhibit Hall A
P9-012
: Epilepsy Monitoring of Prospective Seizure Observations with Electronic Records (EMPOWER): An Observational Study Designed to Better Understand the Patient Journey
Monday, April 7 | 8:00 AM – 9:00 AM PT | Exhibit Hall A
P4-006
: Updates from the First-in-human Phase 1 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Food Effect of Vormatrigine in Healthy Participants
Wednesday, April 9 | 8:00 AM – 9:00 AM PT | Exhibit Hall A
Materials will be made available on the Resources page of the Praxis website following presentation at AAN 2025:
https://praxismedicines.com/resources/
.
About Relutrigine (PRAX-562)
Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathies (DEEs) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in severe DEEs. Relutrigine’s mechanism of precision sodium channel (NaV) modulation is consistent with superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel modulation. Data from the Phase 2 EMBOLD study demonstrated in a heavily pre-treated population a well-tolerated, robust, short- and long-term improvement in motor seizures alongside maintained seizure freedom in some patients with SCN2A- and SCN8A-DEE. Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA, and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE. To learn more about the EMBOLD study, please visit
https://www.emboldstudy.com/
.
About Vormatrigine (PRAX-628)
Vormatrigine is a next-generation, functionally selective small molecule targeting the hyperexcitable state of NaV channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset seizures and generalized epilepsy. Preclinical data demonstrates vormatrigine is differentiated from standard of care, with the potential to be best-in-class for focal onset seizures. In vitro, vormatrigine has demonstrated superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of vormatrigine have demonstrated unprecedented potency in the maximal electroshock seizure (MES) model, a highly predictive translational model for efficacy in focal epilepsy. Data from the PRAX-628-101 study demonstrated that vormatrigine can be safely dosed in healthy subjects to greater than 15 times the predicted human equivalent of the rodent MES EC50, a translational indicator that suggests a therapeutic window with unprecedented magnitude relative to approved therapies.
epilepsy-research.com
About Elsunersen (PRAX-222)
Elsunersen is an antisense oligonucleotide (ASO) designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations. In vitro studies of elsunersen have demonstrated reduction in both SCN2A gene expression and protein levels. In vivo, elsunersen has demonstrated significant, dose-dependent reduction in seizures, improvement in behavioral and locomotor activity and increased survival in SCN2A mouse models. Data from the EMBRAVE study demonstrated well-tolerated, significant and sustained seizure reduction in patients with SCN2A-DEE. Elsunersen has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD) from the FDA, and ODD and PRIME designations from the European Medicines Agency (EMA) for the treatment of SCN2A-DEE. The Elsunersen program is ongoing under a collaboration with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), and RogCon, Inc. To learn more about the EMBRAVE study, please visit
https://www.embravestudy.org/
.
About Ulixacaltamide
Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the cerebello-thalamo-cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide, the most advanced program within Praxis’ Cerebrum™ small molecule platform, is currently in development for the treatment of essential tremor.
www.praxisessentialtremor.com
.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit
www.praxismedicines.com
and follow us on
Facebook
,
Instagram
,
LinkedIn
and
Twitter/X
.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
